Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia

In a murine model of respiratory syncytial virus disease, prior sensitization to the attachment glycoprotein (G) leads to pulmonary eosinophilia and enhanced illness. Three different approaches were taken to dissect the region of G responsible for enhanced disease and protection against challenge. First, mutant viruses, containing frameshifts that altered the COOH terminus of the G protein, were used to challenge mice sensitized by scarification with recombinant vaccinia virus (rVV) expressing wild-type G. Second, cDNA expressing these mutated G proteins were expressed by rVV and used to vaccinate mice before challenge with wild-type respiratory syncytial virus (RSV). These studies identified residues 193–205 to be responsible for G-induced weight loss and lung eosinophilia and showed that this region was not was not necessary for induction of protective immunity. Third, mice were sensitized using an rVV that expressed only amino acids 124–203 of the G protein. Upon RSV challenge, mice sensitized with this rVV developed enhanced weight loss and eosinophilia. This is the first time that a region within RSV (amino acids 193–203) has been shown to be responsible for induction of lung eosinophilia and disease enhancement. Moreover, we now show that it is possible to induce protective immunity with an altered G protein without inducing a pathological response.

[1]  A. O’Garra,et al.  CD8+ T cells control Th2‐driven pathology during pulmonary respiratory syncytial virus infection , 1997, European journal of immunology.

[2]  T. Braciale,et al.  Virus-specific CD8+ T Lymphocytes Downregulate T Helper Cell Type 2 Cytokine Secretion and Pulmonary Eosinophilia during Experimental Murine Respiratory Syncytial Virus Infection , 1997, The Journal of experimental medicine.

[3]  P. Openshaw,et al.  IL-12 treatment attenuates T helper cell type 2 and B cell responses but does not improve vaccine-enhanced lung illness. , 1997, Journal of immunology.

[4]  R. Garofalo,et al.  Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells. , 1997, The Journal of infectious diseases.

[5]  T. Braciale,et al.  Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection , 1997, Journal of virology.

[6]  R. C. Veen Immunogenicity of JHM virus proteins: characterization of a CD4+ T cell epitope on nucleocapsid protein which induces different T-helper cell subsets. , 1996 .

[7]  A. O’Garra,et al.  Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus. , 1996, The Journal of general virology.

[8]  M. Trudel,et al.  Evidence that the amino acid region 124-203 of glycoprotein G from the respiratory syncytial virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection. , 1995, Antiviral research.

[9]  T. Williams,et al.  Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo , 1995, The Journal of experimental medicine.

[10]  F. Schödel,et al.  Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent , 1995, Journal of virology.

[11]  N. Day,et al.  Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Southwood,et al.  Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo , 1995, The Journal of experimental medicine.

[13]  B. Björkstén,et al.  Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. , 1995, Pediatrics.

[14]  J. Orange,et al.  Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids , 1995, The Journal of experimental medicine.

[15]  P. Openshaw,et al.  Distinct types of lung disease caused by functional subsets of antiviral T cells , 1994, The Journal of experimental medicine.

[16]  B. Graham,et al.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. , 1993, Journal of immunology.

[17]  P. Openshaw,et al.  Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. , 1993, Journal of immunology.

[18]  J. Melero,et al.  Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. , 1992, The Journal of general virology.

[19]  P. Openshaw,et al.  CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells , 1992, Clinical and experimental immunology.

[20]  P. Openshaw,et al.  Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. , 1992, International immunology.

[21]  L. A. Bunton,et al.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. , 1991, The Journal of clinical investigation.

[22]  B. García-Barreno,et al.  Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. , 1990, The EMBO journal.

[23]  S. Levine,et al.  Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. , 1987, The Journal of general virology.

[24]  R. Pemberton,et al.  Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. , 1987, The Journal of general virology.

[25]  L. A. Ball,et al.  Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice , 1987, Journal of virology.

[26]  L. A. Ball,et al.  Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge , 1986, Journal of virology.

[27]  G. Meiklejohn,et al.  Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. , 1969, American journal of epidemiology.

[28]  R. Chanock,et al.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. , 1969, American journal of epidemiology.

[29]  R. Chanock,et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.

[30]  E. H. Lennette,et al.  Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. , 1969, American journal of epidemiology.

[31]  R. C. van der Veen Immunogenicity of JHM virus proteins: characterization of a CD4+ T cell epitope on nucleocapsid protein which induces different T-helper cell subsets. , 1996, Virology.

[32]  L. J. Anderson,et al.  Protective and disease-enhancing immune responses to respiratory syncytial virus. , 1995, The Journal of infectious diseases.

[33]  P. Openshaw,et al.  Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. , 1993, Vaccine.